Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.

Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Chemomab Therapeutics Ltd.

Country	Israel
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	20
CEO	Adi George

Contact Details

Address: Building C, 10th Floor Tel Aviv-Yafo, 6158101 Israel
Phone	972 77 331 0156
Website	chemomab.com

Stock Details

Ticker Symbol	CMMB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1534248
CUSIP Number	16385C203
ISIN Number	US16385C2035
Employer ID	81-3676773
SIC Code	2834

Key Executives

Name	Position
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director
Sigal Fattal CPA, M.B.A.	Chief Financial Officer
Jack Lawler	Chief Development Officer
Dr. David M. Weiner M.B.A., M.D.	Interim Chief Medical Officer

Latest SEC Filings

Date	Type	Title
May 6, 2026	6-K	Report of foreign issuer
Apr 28, 2026	6-K	Report of foreign issuer
Mar 23, 2026	20-F	Annual and transition report of foreign private issuers
Mar 20, 2026	6-K	Report of foreign issuer
Mar 19, 2026	6-K	Report of foreign issuer
Feb 17, 2026	SCHEDULE 13G/A	Filing
Feb 10, 2026	SCHEDULE 13G/A	Filing
Nov 21, 2025	6-K	Report of foreign issuer
Aug 22, 2025	6-K	Report of foreign issuer
Aug 14, 2025	6-K	Report of foreign issuer

View All SEC Filings